IL165605A0 - Molecular antigen arrays - Google Patents

Molecular antigen arrays

Info

Publication number
IL165605A0
IL165605A0 IL16560504A IL16560504A IL165605A0 IL 165605 A0 IL165605 A0 IL 165605A0 IL 16560504 A IL16560504 A IL 16560504A IL 16560504 A IL16560504 A IL 16560504A IL 165605 A0 IL165605 A0 IL 165605A0
Authority
IL
Israel
Prior art keywords
antigen
vlp
useful
provides
bound
Prior art date
Application number
IL16560504A
Other languages
English (en)
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of IL165605A0 publication Critical patent/IL165605A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
IL16560504A 2002-07-17 2004-12-07 Molecular antigen arrays IL165605A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39612602P 2002-07-17 2002-07-17
PCT/EP2003/007572 WO2004007538A2 (en) 2002-07-17 2003-07-14 Molecular antigen arrays using a virus like particle derived from the ap205 coat protein

Publications (1)

Publication Number Publication Date
IL165605A0 true IL165605A0 (en) 2006-01-15

Family

ID=30115977

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16560504A IL165605A0 (en) 2002-07-17 2004-12-07 Molecular antigen arrays

Country Status (15)

Country Link
US (3) US7138252B2 (xx)
EP (2) EP2351770A1 (xx)
JP (3) JP4726483B2 (xx)
CN (2) CN1668637B (xx)
AT (1) ATE542828T1 (xx)
AU (1) AU2003246690B2 (xx)
BR (1) BR0312935A (xx)
CA (1) CA2489410C (xx)
HK (1) HK1078880A1 (xx)
IL (1) IL165605A0 (xx)
MX (1) MXPA05000277A (xx)
NZ (1) NZ538083A (xx)
RU (2) RU2324704C2 (xx)
WO (1) WO2004007538A2 (xx)
ZA (1) ZA200410046B (xx)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085208A2 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US20040005338A1 (en) * 2002-06-20 2004-01-08 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
CN1668637B (zh) * 2002-07-17 2010-05-26 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
BR0312792A (pt) * 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
AU2005281743A1 (en) * 2004-08-04 2006-03-16 Cytos Biotechnology Ag Carrier conjugates of GnRH-peptides
MX2007003171A (es) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
CA2588274A1 (en) * 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
EP1809335A2 (en) 2004-10-25 2007-07-25 Cytos Biotechnology AG Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
EP1804829A1 (en) * 2004-10-29 2007-07-11 Cytos Biotechnology AG T-cadherin antigen arrays and uses thereof
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20090123414A1 (en) * 2004-12-13 2009-05-14 Cytos Biotechnology Ag Il-15 Antigen Arrays And Uses Thereof
US7767212B2 (en) * 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof
EP1746165A1 (en) 2005-07-21 2007-01-24 Cytos Biotechnology AG Scalable fermentation process
EP1885847B1 (en) 2005-05-26 2011-07-06 Cytos Biotechnology AG Scalable fermentation process
MX2007015781A (es) * 2005-06-14 2008-02-15 Cytos Biotechnology Ag Conjugados antigenos y sus usos.
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
KR20080047564A (ko) 2005-09-28 2008-05-29 사이토스 바이오테크놀로지 아게 인터루킨-1 컨쥬게이트 및 그의 용도
CA2632662A1 (en) * 2005-12-08 2007-06-14 South Dakota State University Methods of in vitro propagation and detection of infectious prion
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
ES2427994T3 (es) 2006-06-12 2013-11-05 Cytos Biotechnology Ag Procesos para empaquetar oligonucleótidos en partículas de tipo viral de bacteriófagos de ARN
CA2664418A1 (en) * 2006-09-28 2008-04-03 Cytos Biotechnology Ag Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
US7998487B2 (en) * 2007-02-16 2011-08-16 The Salk Institute For Biological Studies Antitoxin and vaccine platform based on nodavirus VLPs
WO2008133141A1 (ja) * 2007-04-24 2008-11-06 Toyo Boseki Kabushiki Kaisha オスモチン組換えタンパク質およびその製造方法、並びにその利用
DK2190473T3 (da) 2007-08-15 2013-03-25 Circassia Ltd Peptid med reduceret dimerdannelse
US8222206B2 (en) * 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
WO2009130261A1 (en) * 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
KR101634058B1 (ko) 2008-12-09 2016-06-27 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
WO2010122164A1 (en) 2009-04-23 2010-10-28 Cytos Biotechnology Ag VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
CN102573915B (zh) * 2009-04-30 2015-02-18 赛托斯生物技术公司 流感血凝素组合物及其用途
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
NZ620441A (en) * 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
WO2011097266A1 (en) 2010-02-02 2011-08-11 Amano Enzyme Usa, Ltd. Use of proteases for gluten intolerance
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
EP2736537A4 (en) 2011-07-29 2015-04-15 Selecta Biosciences Inc SYNTHETIC NANOTRANSPORTERS FOR THE PRODUCTION OF HUMOROUS AND CYTOTOXIC T-LYMPHOCY (CTL) IMMUNE REACTIONS
SG11201403445YA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Full length antibody display system for eukaryotic cells and its use
US20210320597A1 (en) * 2012-05-11 2021-10-14 The Regents Of The University Of California Virus-Based Piezoelectric Energy Generation
DE102013105144A1 (de) * 2013-05-17 2014-11-20 Arno Thaller Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3244915A1 (en) 2015-01-15 2017-11-22 University of Copenhagen Virus-like particle with efficient epitope display
KR20180049061A (ko) * 2015-09-08 2018-05-10 유니베르시태트 취리히 고양이 알레르기 억제 조성물
EP3141600A1 (en) * 2015-09-11 2017-03-15 Institut National de la Recherche Agronomique Nepovirus coat protein fusion polypeptides and their use
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
AU2016341527B2 (en) * 2015-10-22 2023-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
ES2854726T3 (es) 2015-10-30 2021-09-22 The Univ Of Copenhagen Partícula similar a virus con presentación eficiente de epítopos
KR20240042570A (ko) 2016-09-02 2024-04-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2021525058A (ja) 2018-04-09 2021-09-24 チェックメイト ファーマシューティカルズ ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
US20220072120A1 (en) * 2019-02-08 2022-03-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Nanoparticle-based influenza virus vaccines and uses thereof
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
AU2020372478A1 (en) 2019-10-23 2022-06-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
US20230063876A1 (en) * 2020-03-02 2023-03-02 Unm Rainforest Innovations Virus-Like Particle Vaccines for Opioid Drugs
EP4141110A1 (en) 2020-04-24 2023-03-01 Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" Method for producing particles of bacteriophages of the genus levivirus
MX2022014605A (es) 2020-05-19 2022-12-16 Cybin Irl Ltd Derivados de triptamina deuterada y metodos de uso.
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114632148A (zh) * 2020-12-15 2022-06-17 榕森生物科技(北京)有限公司 病原样抗原疫苗及其制备方法
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
CN112480245B (zh) * 2020-12-19 2023-08-18 上海佰君生物科技有限公司 一种疏水性环状肽配基纯化人免疫球蛋白g的应用
EP4323397A1 (en) 2021-04-12 2024-02-21 Saiba AG Modified virus-like particles of bacteriophage ap205
WO2022229817A1 (en) 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
WO2024068265A2 (en) 2022-09-30 2024-04-04 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
CN116987700B (zh) * 2023-07-13 2024-02-20 杭州赛基生物科技有限公司 一种人白细胞介素-5重组蛋白及其制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334A (en) * 1847-10-16 Improvement in cutter-heads for plan ing-machines
US394A (en) * 1837-09-21 Mode of regulating the temperature of inkiwg-rollers and ink used
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
BR8707471A (pt) 1986-09-22 1988-09-13 Univ Emory Vacina e processo de preparacao
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69018926T2 (de) 1989-09-04 1995-08-24 Wellcome Found Vakzine gegen Bordetella.
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
AU9052091A (en) 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
ES2131676T3 (es) 1993-01-11 1999-08-01 Dana Farber Cancer Inst Inc Induccion de respuestas con linfocitos t citotoxicos.
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
DK0885244T4 (da) 1996-03-01 2008-06-16 Novartis Ag Peptidimmunogener til vaccination imod og til behandling af allergi
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
CA2297786C (en) 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie New immunoprotective influenza antigen and its use in vaccination
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
DE69911175T2 (de) 1998-02-12 2004-07-29 Apovia, Inc., San Diego Strategisch modifizierte hepatitis b kernproteine und ihre derivate
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
WO2000023955A1 (en) 1998-10-21 2000-04-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Virus-like particles for the induction of autoantibodies
US6380364B1 (en) 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
BR9915771A (pt) * 1998-11-30 2001-12-26 Cytos Biotechnology Ag Apresentação molecular ordenada de antìgenos,processo de preparação e utilização
EP1135408B1 (en) 1998-12-04 2011-09-21 Biogen Idec MA Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
CN1520423A (zh) 1999-02-25 2004-08-11 ʷ��˿�������ȳ�ķ���޹�˾ 来源于IgE的Cε3或Cε4区的抗原决定基或拟表位,其拮抗物,及其治疗用途
WO2000059928A1 (en) 1999-04-07 2000-10-12 Thomas Jefferson University Chemokine-derived synthetic peptides
JP5025871B2 (ja) 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
DE60222917T2 (de) 2001-09-21 2008-08-07 Coloplast A/S Vorrichtung zur verabreichung eines wirkstoffes an die menschliche haut
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
ATE412428T1 (de) * 2001-11-07 2008-11-15 Cytos Biotechnology Ag Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
JP3787697B2 (ja) 2002-01-08 2006-06-21 独立行政法人理化学研究所 重イオンビーム照射によるキメラ植物の作出方法
CN1668637B (zh) * 2002-07-17 2010-05-26 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
US6932971B2 (en) * 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
BR0312792A (pt) * 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
ZA200507063B (en) * 2003-03-26 2007-03-28 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: Method of preparation and use
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CA2533660C (en) 2003-07-25 2013-04-23 Agroplast Aps Method and system for treating waste matter from animals containing urea
EP1809335A2 (en) * 2004-10-25 2007-07-25 Cytos Biotechnology AG Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
US7767212B2 (en) * 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof

Also Published As

Publication number Publication date
CN102061288A (zh) 2011-05-18
JP2006510347A (ja) 2006-03-30
NZ538083A (en) 2006-08-31
EP2351770A1 (en) 2011-08-03
US20040076611A1 (en) 2004-04-22
WO2004007538A2 (en) 2004-01-22
RU2005104235A (ru) 2005-09-10
US7494656B2 (en) 2009-02-24
US7138252B2 (en) 2006-11-21
JP2010075196A (ja) 2010-04-08
US20100092508A1 (en) 2010-04-15
EP1532167A2 (en) 2005-05-25
AU2003246690B2 (en) 2010-03-11
MXPA05000277A (es) 2005-03-31
HK1078880A1 (en) 2006-03-24
CN1668637A (zh) 2005-09-14
BR0312935A (pt) 2005-06-21
ATE542828T1 (de) 2012-02-15
JP4726483B2 (ja) 2011-07-20
EP1532167B1 (en) 2012-01-25
AU2003246690A1 (en) 2004-02-02
CA2489410A1 (en) 2004-01-22
JP2011087580A (ja) 2011-05-06
WO2004007538A3 (en) 2004-03-04
CN1668637B (zh) 2010-05-26
ZA200410046B (en) 2006-03-29
RU2007144895A (ru) 2009-06-10
CA2489410C (en) 2015-01-13
US20070128219A1 (en) 2007-06-07
RU2324704C2 (ru) 2008-05-20

Similar Documents

Publication Publication Date Title
IL165605A0 (en) Molecular antigen arrays
MX2007003171A (es) Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
WO2002056905A3 (en) Molecular antigen array
IL166227A0 (en) Vaccine compositions containing amyloid beta1-6 antigen arrays
WO2006097530A3 (en) Cat allergen fusion proteins and uses thereof
IL165003A0 (en) Ghrelin-carrier conjugates
HK1068355A1 (en) Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases
WO2006045796A3 (en) Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
WO2006063974A3 (en) Il-15 antigen arrays and uses thereof
WO2006027300A3 (en) Carrier conjugates of gnrh-peptides
WO2005068639A3 (en) Particle-induced ghrelin immune response
WO2005117983A3 (en) Carrier conjugates of tnf-peptides
IL161146A0 (en) Antigen arrays for treatment of bone disease
MXPA04003901A (es) Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas.
WO2007008093A3 (en) A method of manufacturing a recombinant vaccine against viral rabbit haemorrhagic disease, the vaccine, the application of a recombinant antigen in the manufacture of the vaccine
MXPA04003900A (es) Disposiciones de antigenos para el tratamiento de enfermedades oseas.
WO2003074003A3 (en) Immunogens for treatment of neoplastic and infectious disease